宣泰医药：注射用硫酸艾沙康唑获得国家药品监督管理局批准

Core Viewpoint - The company, Xuantai Pharmaceutical (688247.SH), has received approval from the National Medical Products Administration (NMPA) for the marketing of its injectable Isavuconazole sulfate, which is indicated for the treatment of invasive fungal infections in adult patients [1] Group 1 - The injectable Isavuconazole sulfate is approved for the treatment of invasive aspergillosis and invasive mucormycosis [1]